ArticleInternational journal of genomics2014
A Meta-Analysis on the Relations between EGFR R521K Polymorphism and Risk of Cancer.
Article in International journal of genomics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Meta-analysis ofInternational journal of immunopathology and pharmacologyPooled it
- Exploring the mutational spectrum of key kinase genes PIK3CA, BRAF, EGFR, ALK and ROS1 in oral squamous cell carcinoma.BMC cancer · 2025Article
- High Prevalence of EGFR R479K (rs2227983) Polymorphism in Indian Head and Neck Cancer Patients: Association with Unfavourable Clinical Outcome.Asian Pacific journal of cancer prevention : APJCP · 2025Article
- Experimental System Design and Modelling of EGFR Extracellular Domain and Its Mutant Binding to Antibody Interacting Partner.International journal of molecular sciences · 2025Article
- Review
- The Investigation of Associations betweenDiagnostics (Basel, Switzerland) · 2021Article
- Role of EGFR gene polymorphisms in oral squamous cell carcinoma patients of Southeast Iran: A case-control study.Caspian journal of internal medicine · 2020Article
- Stapled EGFR peptide reduces inflammatory breast cancer and inhibits additional HER-driven models of cancer.Journal of translational medicine · 2019Article
- The Association between Epidermal Growth Factor Receptor (Biomolecules · 2018Article
- Evaluation of the EGFR polymorphism R497K in two cohorts of neoadjuvantly treated breast cancer patients.PloS one · 2017Article
- The Relations between EGFR R521K Polymorphism and Risk of Cancer: Need for Clarification of Data in a Recent Meta-Analysis.International journal of genomics · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The EGFR R521K polymorphism has been shown to reduce the activity of EGFR; however, the association between EGFR R521K polymorphism and the risk of cancer remains inconclusive; therefore we performed a meta-analysis to evaluate the relationship between EGFR R521K polymorphism and susceptibility to cancer. Our results suggest that the EGFR R521K polymorphism is not associated with risk of cancer, but the different chemosensitivity to anticancer drugs may need further investigation.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.